At Emergent, we develop, manufacture, and deliver protections against public health threats. For more than two decades, we’ve been at work defending people from things we hope will never happen — so that we’re prepared, just in case they ever do.
Having over-the-counter (OTC) naloxone gives us the opportunity to make it mainstream where it hasn’t been before. The teamwork, hard work, and collaboration that has brought us to this point is essential to me. We have been able to bring this product to OTC because of accessibility, barrier removal, and the opportunity for everyone to have access.
Denials are no longer a slow leak in the revenue cycle—they’re a fast-moving, rule-shifting game controlled by payers, and hospitals that don’t model denial patterns in real time end up budgeting around losses they could have prevented. PayerWatch’s four-digit, client-verified ROI in 2024 shows what happens when a hospital stops reacting claim by…
Health insurers love to advertise themselves as guardians of care, but the real story often begins when a patient’s life no longer fits neatly into a spreadsheet. In oncology especially, “coverage” isn’t a bureaucratic checkbox—it’s the fragile bridge between a treatment that finally works and a relapse that can undo years of grit…
In “Fighting for Coverage,” a patient describes a double war: the physical fight to stay alive and the bureaucratic fight to prove to an insurer that her life is worth the cost. Her account spotlights a core tension in the U.S. system—coverage decisions are increasingly shaped by prior authorizations and desk-based reviewers who…